HOSPITAL/COMMUNITY PHARMACIST SHARING OF EXPERTISE
HOSPITAL/COMMUNITY PHARMACIST SHARING OF EXPERTISE could improve overall patient care, APhA President Jack Schlegel urged in an Oct. 11 address to the Maryland Society of Hospital Pharmacists, in Baltimore. He suggested that not only should community pharmacists, under APhA's plan to develop residencies, have some training in the hospital environment, but that hospital-pharmacist residents should spend some time in the community pharmacy. Suggesting a need for "complementary roles" by hospital and community pharmacists in monitoring drug therapy for outpatients and providing services for home care, Schlegel urged: "We all must work diligently to remove the clinical versus traditional pharmacy attitude and reality. Clinical means patient care, and that is what our profession is all about." Schlegel asked the hospital pharmacists "to work with us as we work toward raising the level of pharmacy practice and offer all pharmacists opportunities to rise above what some refer to as counting and pouring functions." He added: "You who are privileged to work in institutions where you do have sophisticated programs, where the use of new technologies is at its highest and where opportunities for education and training abound, must share your experiences, resources, and expertise with pharmacists practicing in other settings." Pharmacist-sharing of experiences and expertise was seen by the APhA president "as essential to advancing our profession as a whole. To isolate small segments of the profession can only weaken our position wherever we must make a stand." Day-to-day experience of clinical practitioners in working more closely with patients, MDs and other providers "has shown the way for their colleagues," Schlegel declared, admonishing: "But you who are clinical pharmacists must now come out of splendid institutional isolation and take leadership in the profession to implement clinical practice in the community practice setting. Clinical pharmacy practice -- with all its specialties -- should not be unique to only a few. We are first pharmacists; all else follows."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth